Do analysts rate CGC or PLYX?

Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 258.26%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger valuation & earnings, AVIR or PLYX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A

Is AVIR or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% Polaryx Therapeutics N/A N/A N/A

Which has preferable earnings and valuation, PLYX or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is PLYX or TTRX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Turn Therapeutics N/A -230.84% -53.19%

Polaryx Therapeutics (PLYX) Competitors

$2.14 -0.01 (-0.47%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.62 -0.52 (-24.25%)

As of 04:01 AM Eastern

Compare

PLYX vs. CGC, AVIR, SPRY, TTRX, and FENC

Should you buy Polaryx Therapeutics stock or one of its competitors? Polaryx Therapeutics's main competitors and comparable companies include Canopy Growth (CGC), Atea Pharmaceuticals (AVIR), ARS Pharmaceuticals (SPRY), Turn Therapeutics (TTRX), and Adherex Technologies (FENC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Polaryx Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

In the previous week, Canopy Growth had 22 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 22 mentions for Canopy Growth and 0 mentions for Polaryx Therapeutics. Canopy Growth's average media sentiment score of 1.09 beat Polaryx Therapeutics' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Canopy Growth	Positive
Polaryx Therapeutics	Neutral

Polaryx Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Polaryx Therapeutics' return on equity of 0.00% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Polaryx Therapeutics	N/A	N/A	N/A

3.3% of Canopy Growth shares are owned by institutional investors. 0.4% of Canopy Growth shares are owned by insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Polaryx Therapeutics has lower revenue, but higher earnings than Canopy Growth. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$293.63M	1.43	-$190.29M	-$0.45	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 258.26%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Polaryx Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Polaryx Therapeutics beats Canopy Growth on 9 of the 14 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Atea Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 32.58%. Polaryx Therapeutics has a consensus target price of $7.67, indicating a potential upside of 258.26%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Polaryx Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Polaryx Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Atea Pharmaceuticals' average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Polaryx Therapeutics	Neutral

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Polaryx Therapeutics beats Atea Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Polaryx Therapeutics compare to ARS Pharmaceuticals?

Polaryx Therapeutics (NASDAQ:PLYX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Polaryx Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
ARS Pharmaceuticals	$84.28M	4.93	-$171.30M	-$2.18	N/A

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Polaryx Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 258.26%. ARS Pharmaceuticals has a consensus price target of $26.40, indicating a potential upside of 531.58%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ARS Pharmaceuticals had 21 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 21 mentions for ARS Pharmaceuticals and 0 mentions for Polaryx Therapeutics. ARS Pharmaceuticals' average media sentiment score of 0.12 beat Polaryx Therapeutics' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
ARS Pharmaceuticals	Neutral

Polaryx Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Polaryx Therapeutics' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Summary

Polaryx Therapeutics beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Turn Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

In the previous week, Turn Therapeutics had 2 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.26 indicating that Polaryx Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Turn Therapeutics	Neutral

Polaryx Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 258.26%. Turn Therapeutics has a consensus target price of $9.00, indicating a potential downside of 33.38%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Polaryx Therapeutics' return on equity of 0.00% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Turn Therapeutics	N/A	-230.84%	-53.19%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Summary

Polaryx Therapeutics beats Turn Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Polaryx Therapeutics compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Adherex Technologies currently has a consensus target price of $17.00, suggesting a potential upside of 61.75%. Polaryx Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 258.26%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Polaryx Therapeutics' return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-6.09%	-5.71%	-2.37%
Polaryx Therapeutics	N/A	N/A	N/A

55.5% of Adherex Technologies shares are owned by institutional investors. 10.7% of Adherex Technologies shares are owned by company insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Polaryx Therapeutics has lower revenue, but higher earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Polaryx Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	8.25	-$9.74M	-$0.13	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

In the previous week, Adherex Technologies had 3 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 3 mentions for Adherex Technologies and 0 mentions for Polaryx Therapeutics. Adherex Technologies' average media sentiment score of 0.45 beat Polaryx Therapeutics' score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Neutral
Polaryx Therapeutics	Neutral

Summary

Polaryx Therapeutics beats Adherex Technologies on 10 of the 15 factors compared between the two stocks.

Get Polaryx Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLYX vs. The Competition

Export

Metric	Polaryx Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$107.17M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-26.75	792.28	274.09	25.69
Price / Sales	N/A	861.37	642.55	79.71
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	21.40	10.58	10.47	6.32
Net Income	-$8.98M	$2.81B	$3.49B	$359.73M
7 Day Performance	N/A	-0.12%	-0.68%	0.17%
1 Month Performance	14.44%	-1.34%	-3.18%	-3.27%
1 Year Performance	N/A	2.86%	15.12%	5.58%

Polaryx Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLYX Polaryx Therapeutics	2.5969 of 5 stars	$2.14 -0.5%	$7.67 +258.3%	N/A	$107.17M	N/A	N/A	11
CGC Canopy Growth	1.0749 of 5 stars	$0.93 -0.5%	N/A	-28.6%	$421.94M	$251.01M	N/A	1,128	Trending News Options Volume
AVIR Atea Pharmaceuticals	1.7538 of 5 stars	$5.33 +1.3%	$7.00 +31.3%	+82.1%	$421.88M	N/A	N/A	55	High Trading Volume
SPRY ARS Pharmaceuticals	1.7375 of 5 stars	$4.11 -1.0%	$26.40 +542.3%	-57.9%	$412.71M	$84.28M	N/A	200	Trending News
TTRX Turn Therapeutics	1.4802 of 5 stars	$14.94 +8.1%	$9.00 -39.8%	N/A	$411.67M	N/A	N/A	2	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLYX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. CGC, AVIR, SPRY, TTRX, and FENC

How does Polaryx Therapeutics compare to Canopy Growth?

Summary

How does Polaryx Therapeutics compare to Atea Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to ARS Pharmaceuticals?

Summary

How does Polaryx Therapeutics compare to Turn Therapeutics?

Summary

How does Polaryx Therapeutics compare to Adherex Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Polaryx Therapeutics (PLYX) Competitors

PLYX vs. CGC, AVIR, SPRY, TTRX, and FENC

How does Polaryx Therapeutics compare to Canopy Growth?

Does the media favor CGC or PLYX?

Is CGC or PLYX more profitable?

Do insiders and institutionals believe in CGC or PLYX?

Which has preferable earnings & valuation, CGC or PLYX?

Do analysts rate CGC or PLYX?

Summary

How does Polaryx Therapeutics compare to Atea Pharmaceuticals?

Do analysts rate AVIR or PLYX?

Which has stronger valuation & earnings, AVIR or PLYX?

Is AVIR or PLYX more profitable?

Does the media favor AVIR or PLYX?

Do institutionals & insiders believe in AVIR or PLYX?

Summary

How does Polaryx Therapeutics compare to ARS Pharmaceuticals?

Which has better valuation and earnings, PLYX or SPRY?

Do institutionals and insiders believe in PLYX or SPRY?

Do analysts rate PLYX or SPRY?

Does the media prefer PLYX or SPRY?

Is PLYX or SPRY more profitable?

Summary

How does Polaryx Therapeutics compare to Turn Therapeutics?

Does the media favor PLYX or TTRX?

Do analysts prefer PLYX or TTRX?

Is PLYX or TTRX more profitable?

Which has preferable earnings and valuation, PLYX or TTRX?

Summary

How does Polaryx Therapeutics compare to Adherex Technologies?

Do analysts recommend FENC or PLYX?

Is FENC or PLYX more profitable?

Do institutionals and insiders have more ownership in FENC or PLYX?

Which has preferable valuation and earnings, FENC or PLYX?

Does the media prefer FENC or PLYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLYX vs. The Competition

Polaryx Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools